Middle-molecule uremic toxin removal via hemodialysis augmented with an immunosorbent packed bed

Shu Xia, Nichole Hodge, Melvin Laski, Theodore F. Wiesner

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Outcomes for hemodialysis patients are disappointing. Middle molecules too large to cross dialysis membranes, such as parathyroid hormone (PTH), accumulate in the blood and are implicated in a complex collection of symptoms known as the uremic syndrome. We report our investigation into the removal of middle molecules by adding an immunosorptive packed bed, known as a hemoperfuser, to hemodialysis. We established in vitro that PTH can be reduced to normal levels within a typical dialysis session. We then developed a mathematical model of a combined hemodialysis-hemoperfusion system integrated with a patient pharmacokinetics model. We validated the model in vitro and then scaled up it up to clinical practice. We predict that immunosorptive hemoperfusion can reduce PTH levels to the normal range within the clinical scenario as well. However, we also predict that, because of the high synthesis rate of PTH in vivo, the toxin concentration might recover so rapidly as to limit the effectiveness of added immunosorption.

Original languageEnglish
Pages (from-to)1359-1369
Number of pages11
JournalIndustrial and Engineering Chemistry Research
Issue number3
StatePublished - Feb 3 2010


Dive into the research topics of 'Middle-molecule uremic toxin removal via hemodialysis augmented with an immunosorbent packed bed'. Together they form a unique fingerprint.

Cite this